Medios AG: Acquisition of Blisterzentrum Baden-Württemberg GmbH and expansions in the area of sterile manufacturing

Medios AG / Key word(s): Takeover/Contract
Medios AG: Acquisition of Blisterzentrum Baden-Württemberg GmbH and expansions in the area of sterile manufacturing

22-Nov-2022 / 13:06 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014

Acquisition of Blisterzentrum Baden-Württemberg GmbH and expansions in the area of sterile manufacturing

Berlin, November 22, 2022 – Medios AG ("Medios") today entered into a purchase agreement for the acquisition of Blisterzentrum Baden-Württemberg GmbH ("bbw") and agreed on a cooperation in the field of sterile manufacturing with Apotheken für Spezialversorgungen OHG ("AfS").

bbw is a pharmaceutical manufacturing company that produces patient-specific blister packs on behalf of pharmacies. In addition to the manufacturing license, the company holds a wholesale license and distributes finished medicinal products from the Specialty Pharma sector that are approved in Germany.

The pharmacies operated by AfS are primarily active in the specialty pharmaceuticals sector (manufacture and supply of patient-specific infusion therapies and of ophthalmological sterile preparations) in southern Germany. The agreement provides for AfS to cooperate with the Medios Group in the manufacture and supply of patient-specific preparations. The volume expected by Medios is approximately 70,000 additional patient-specific preparations per year.

bbw and the sterile manufacturing business covered by the collaboration represent expected revenue of approximately €75 million and EBITDA* of approximately €6.8 million in the 2022 financial year. The consideration to be paid by Medios amounts to slightly more than €30 million and will be provided from freely available liquidity and, if required, from available credit lines, with more than one third being performance-based and paid over a period of two years.

In addition to the usual closing conditions, the closing is also subject to approval by the German Federal Cartel Office. Closing is expected for early 2023.

* EBITDA is defined as earnings before interest, taxes, depreciation and amortization.

Person communicating: Matthias Gärtner, Chairman of the Executive Board

Contact

Medios AG, Heidestrasse 9, 10557 Berlin, Germany

Phone: +49 30 232 5668 00; Fax: +49 30 232 5668 01

E-mail: ir@medios.ag; www.medios.ag

-------------------

About Medios AG

Medios AG is the leading provider of Specialty Pharma Solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies.

Medios AG is Germany's first listed Specialty Pharma company and is included in the SDAX selection index. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).

www.medios.ag

Contact

Claudia Nickolaus

Head of Investor & Public Relations, ESG Communications

Medios AG

Heidestraße 9 | 10557 Berlin

T +49 30 232 566 800

c.nickolaus@medios.ag

www.medios.ag

Disclaimer

This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing.

22-Nov-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com